Skip to main content
. 2015 Mar 11;26(6):367–376. doi: 10.1089/hum.2014.130

Table 3.

Disease Status at the End of the Study and Causes of Death

  ST (n=162) CT (n=301) CT vs. ST
Attribute CS-ST (n=98) PS-ST (n=64) CS-CT (n=185) PS-CT (n=116) p <
Patients n (%) n (%) n (%) n (%) CS PS
 Local disease-free 11 (11.2) 0 154 (83.2) 0 4.8×10−16
 Disease-free 1 (1.0) 0 136 (73.5) 0 1.5×10−15
Metastasis-free: M0 43 (43.9) 31 (48.4) 165 (89.2) 95 (81.9) 1.8×10−15 6.5×10−6
Bearing metastasis: M1 55 (56.1) 33 (51.6) 20 (10.8) 21 (18.1)    
M1
 M0-1 49 (50.0) 26 (40.6) 9 (4.9) 9 (7.8) 0.00018 0.00968
 M1-1 6 (6.1) 7 (10.9) 11 (6.0) 12 (10.3)    
Alive 0 0 54 (29.2) 21 (18.1)
Dropped out treatment 0 0 13 (7.0) 5 (4.3)
Death 98 (100) 64 (100) 118 (63.8) 90 (77.6)
Cause of death CS-ST (n=98) PS-ST (n=64) CS-CT (n=118) PS-CT (n=90) p <
Patients n (%) n (%) n (%) n (%) CS PS
 Local disease (LD) 42 (42.9) 31 (48.4) 31 (26.3) 62 (68.9) 0.01384 0.01250
 Metastases (M) 55 (56.1) 33 (51.6) 18 (15.3) 21 (23.3) 2.4×10−10 0.00054
 Disease (LD+M) 97 (99.0) 64 (100) 49 (41.6) 83 (92.2) 6.1×10−16 0.04182
 Unrelated diseases 1 (1.0) 0 (0) 69 (58.5) 7 (7.8)    

CR, complete response; disease-free patients, dead or alive patients without any evidence of disease at the end of the study; local disease-free patients, patients that did not display postsurgical relapse at the end of the study after one or more complete (CS) or partial (PS) surgeries; M0, patients free of distant metastasis all along the treatment; M0-1, dogs that developed distant metastasis during the treatment; M1, animals bearing distant metastases at the end of the treatment; M1-1, patients with distant metastases all along the treatment.

Patients were clinically evaluated and treated as described in Materials and Methods. p-Values were calculated by two-tailed Fisher's exact test.